CARGO Therapeutics Inc Sustainability Reports
A clinical-stage biotechnology company focused on designing, engineering, and developing next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG01D59LZS4
1 reports from 2023 to 2023
Company Profile
A clinical-stage biotechnology company focused on designing, engineering, and developing next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
